TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3277419
Drug: Captopril 12.5
Normalized name: captopril 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5 to 50 mg twice daily
Study: 31018682
Drug: Dipeptidyl peptidase-4
Normalized name: Immature tripeptidyl-peptidase I
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dipeptidyl peptidase-4 inhibitors
Study: 25955246
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta (two doses)
Study: 16846545
Drug: RSV 10
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV 10 mg/day
Study: 16846545
Drug: RSV 10
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV 10 mg/day and ATV 20 mg/day
Study: 12775859
Drug: Baseline lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline lung function and bronchodilator responsiveness measured using impulse oscillometry (IOS)
Study: 11588893
Drug: Single supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single supplements of vitamin C or E
Study: 11588893
Drug: Antioxidant mixtures
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant mixtures or single supplements of vitamins A and D, zinc, or beta-carotene
Study: 11588893
Drug: Vitamins A,
Normalized name: vitamins A,C,and D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins A, C, and D intake from supplements
Study: 11588893
Drug: Beta-carotene, folate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene, folate, and zinc intake from supplements
Study: 9614950
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy and radiotherapy
Study: 7863731
Drug: Mebendazole (Janssen)
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole (Janssen) given twice daily for three days
Study: 7863731
Drug: Mebendazole (Janssen)
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole (Janssen) single-dose treatment
Study: 2491829
Drug: Oral lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lithium carbonate 1200 mg daily
Study: 29106693
Drug: Individualized metacognitive
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized metacognitive therapy (MCT+)
Study: 26526324
Drug: High number
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High number of different sexual partners (vaginal and oral)
Study: 16029401
Drug: i.v. paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. paracetamol 15 mg.kg(‐1)
Study: 16029401
Drug: propacetamol 30
Normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: propacetamol 30 mg.kg(‐1)
Study: 12505969
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of 2% lidocaine sprayed down the ETT 5 min before extubation (Group 2)
Study: 12505969
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (Group 1)
Study: 12212217
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg.kg‐1 combined with Ketamine
Study: 25135803
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention in a monitoring program for CKD patients, including daily follow-up and recommendations for dose adjustments of nephrotoxic drugs.
Study: 7756047
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pre-treatment alkaline phosphatase and alkaline phosphatase half-life
Study: 7756047
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pre-treatment hydroxyproline and hydroxyproline half-life
Study: 2319516
Drug: Intravenous 'minipulse'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 'minipulse' (100 mg) methylprednisolone (MP) therapy
Study: 2319516
Drug: Standard pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pulse (1000 mg) methylprednisolone (MP) therapy
Study: 583022
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg treptilamine i.v.
Study: 583022
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg treptilamine p.o.
Study: 31866190
Drug: Dantrolene (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dantrolene (1 cap, 25 mg three times daily, or two times daily if not tolerable)
Study: 18707785
Drug: Low boost
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low boost dose of 10 Gy
Study: 18707785
Drug: High boost
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High boost dose of 26 Gy
Study: 11735866
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of i.v. ampicillin, gentamicin, and clindamycin followed by p.o. amoxicillin and clavulanate potassium plus metronidazole (n = 16)
Study: 11735866
Drug: Conversion to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversion to oral therapy
Study: 8172790
Drug: Vinorelbine (NVB)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (NVB) 30 mg/m2/week
Study: 8172790
Drug: Vinorelbine (NVB)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (NVB) 30 mg/m2/week plus Cisplatin (DDP) 80 mg/m2/3 weeks
Study: 25632741
Drug: Salvia Miltiorrhiza
Normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia Miltiorrhiza (1 g each time, three times per day till one month after PCI)
Study: 15124679
Drug: Treosulfan/fludarabine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan/fludarabine (3 x 10 g/m2 of treosulfan with 5 x 30 mg/m2 of fludarabine)
Study: 15124679
Drug: Treosulfan (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treosulfan (escalated from 3 x 10 to 3 x 12 and 3 x 14 g/m2)
Study: 10865808
Drug: recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant growth hormone (rhGH) for the first six months
Study: 10865808
Drug: recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant growth hormone (rhGH) for the second six months
Study: 10865808
Drug: recombinant growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant growth hormone (rhGH) for both groups in the second six months
Study: 3446162
Drug: Low pH
Normalized name: yellow phenolphthalein
DrugBank: Phenolphthalein (DB04824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pH intravenous immunoglobulin
Study: 3446162
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous immunoglobulin
Study: 21649612
Drug: Tetracycline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (500 mg/day × 14 days/month × 3 months)
Study: 18022183
Drug: Repeating the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating the solutions
Study: 8290450
Drug: Povidone-iodine (PVP-I)
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine (PVP-I) ointment
Study: 11948829
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) preparation
Study: 30222643
Drug: Fasting only
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting only (FO) preparation
Study: 25538086
Drug: High-sensitivity troponin
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity troponin I (hsTnI) assay (Erenna, 99th percentile 9 pg/ml)
Study: 16854276
Drug: CHB patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHB patients with HBV DNA > 10^7 copies/ml
Study: 12727933
Drug: Replacement-dose r‐metHuLeptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement-dose r‐metHuLeptin during fasting
Study: 12727933
Drug: Low-dose r‐metHuLeptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose r‐metHuLeptin
Study: 10733492
Drug: Chemotherapy (CTx)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CTx) after MOPP/ABV
Study: 10733492
Drug: Chemotherapy (CTx)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CTx) after ABVPP
Study: 8958889
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion at 20-80 micrograms/kg/min
Study: 8958889
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion with oxygen administration
Study: 2868581
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg at bedtime for 6 months
Study: 2868581
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg at bedtime for 12 months
Study: 28639216
Drug: 200 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 µg selexipag (Treatment A)
Study: 28639216
Drug: 4 paediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 paediatric tablets of 50 µg selexipag (Treatment B)
Study: 24412554
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Nigella sativa L. seeds (NS) once daily for four weeks
Study: 24412554
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg placebo once daily for four weeks
Study: 24568073
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (635 mg EPA, 195 mg DHA)
Study: 17227907
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg of venlafaxine (low‐dose study)
Study: 17227907
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of venlafaxine (high‐dose study)
Study: 11593906
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment for localized disease (n=223)
Study: 11593906
Drug: Primary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary treatment with radiotherapy (n=75) or radical prostatectomy (n=2) +/- hormonal treatment (n=77)
Study: 30113350
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (bolus 0.2 mg/kg over 30 min followed by 0.12 mg/kg/h for 24 h)
Study: 30113350
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (in opioid-naïve patients)
Study: 17617382
Drug: Intranasal application
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal application of 24 IU oxytocin
Study: 9820705
Drug: Antithrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin III (AT III) treatment
Study: 9502783
Drug: L-2-Oxothiazolidine-4-carboxylic acid
Normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-2-Oxothiazolidine-4-carboxylic acid (OTC) 4.5 g
Study: 6922470
Drug: Medication clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication clinic
Study: 30894279
Drug: serlopitant, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: serlopitant, 5 mg, orally once daily for 8 weeks
Study: 30894279
Drug: placebo, orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, orally once daily for 8 weeks
Study: 27930386
Drug: GCSF 300
Normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCSF 300 μg twice daily for 5 days plus standard medical therapy (SMT)
Study: 16460630
Drug: Alcohol gel
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol gel
Study: 11404722
Drug: OAC7 (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC7 (Omeprazole 20 mg b.i.d., Amoxycillin 1 g, Clarithromycin 500 mg)
Study: 11404722
Drug: OAM7 (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM7 (Omeprazole 20 mg b.i.d., Amoxycillin 1 g, Metronidazole 500 mg)
Study: 11404722
Drug: OTA7 (Omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTA7 (Omeprazole 20 mg b.i.d., Tetracycline 500 mg t.i.d., Amoxycillin 1 g b.i.d.)
Study: 10421667
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b + placebo (monotherapy)
Study: 10421667
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b + ribavirin (combination therapy)
Study: 2750673
Drug: Warfarin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (2.5 mg/day, adjusted to lower VIIc to 70% of standard and increase prothrombin time INR to 1.6)
Study: 2750673
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dose sequence as warfarin)
Study: 2750673
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (low-dose warfarin and low-dose aspirin 75 mg/day)
Study: 835781
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) chemotherapy to the point of toxicity
Study: 23232805
Drug: Oral doxifluridine
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral doxifluridine (800 mg/m2/day) in 3 divided doses
Study: 23232805
Drug: Oral uracil/tegafur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral uracil/tegafur (UFT) (400 mg/m2/day) in 2 divided doses
Study: 19671372
Drug: Topical mometasone
Normalized name: mometasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mometasone 50 micrograms in each nostril once daily for 3 months
Study: 19671372
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray once daily for 3 months
Study: 19671372
Drug: Topical mometasone
Normalized name: mometasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mometasone
Study: 17057920
Drug: Amiodarone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (600 mg three times a day, started 30-56 hours before surgery)
Study: 11225504
Drug: Individual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual and group Cognitive Behavioral Therapy (CBT) and family anxiety management training
Study: 11225504
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors, buspirone, and high‐potency benzodiazepines
Study: 11225504
Drug: Psychotherapy, pharmacotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy, pharmacotherapy, and both
Study: 9433396
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg CGP 51901
Study: 9433396
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg CGP 51901
Study: 9433396
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg CGP 51901
Study: 31794072
Drug: SM-1 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM-1 (a combination of diphenhydramine, zolpidem delayed release, and lorazepam delayed release)
Study: 23127290
Drug: Maintenance cognitive
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance cognitive behavior therapy (M-CBT)
Study: 23127290
Drug: Residual symptoms
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual symptoms of agoraphobia at the end of acute-phase treatment
Study: 22103994
Drug: Clinical findings
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical findings (oral thrush, hepatomegaly, lymphadenopathy, etc.)
Study: 18925985
Drug: 2 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Hz rTMS treatment
Study: 16968234
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron orally twice a day for 3 months
Study: 11524329
Drug: small‐dose nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: small‐dose nalbuphine (0.2 microg/mL)
Study: 11524329
Drug: large‐dose nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: large‐dose nalbuphine (0.4 microg/mL)
Study: 11524329
Drug: atropine (1‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: atropine (1‐mg bolus and 0.5 mg/h)
Study: 9263382
Drug: Drug A
Normalized name: Drug additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug A (antidepressant immediate-release product)
Study: 9263382
Drug: Drug B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug B (antiepileptic controlled release product)
Study: 8348164
Drug: hCG therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG therapy
Study: 24275453
Drug: Inspiratory and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory and expiratory muscle training (Threshold Inspiratory Muscle Trainer and Threshold Positive Expiratory Pressure) for 15 minutes each, twice a day, five days/week for eight weeks
Study: 15709984
Drug: Pre-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment with a proton pump inhibitor
Study: 15709984
Drug: No pre-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre-treatment with a proton pump inhibitor
Study: 10509497
Drug: 10 parts
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 parts per million (ppm) inhaled nitric oxide
Study: 10509497
Drug: Control ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control ventilation therapy without nitric oxide
Study: 1942779
Drug: 1 liter
Normalized name: ISOPROPYL ALCOHOL 75 mL in 100 mL TOPICAL GEL [Hand Sanitizer Cristal Prime 1 liter]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 liter of 0.9% saline administered i.v. over one hour prior to amphotericin B
Study: 1942779
Drug: 1 liter
Normalized name: ISOPROPYL ALCOHOL 75 mL in 100 mL TOPICAL GEL [Hand Sanitizer Cristal Prime 1 liter]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 liter of 5% dextrose in water administered i.v. over one hour prior to amphotericin B
Study: 26639039
Drug: Aspirin reaction
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin reaction units >550
Study: 19683936
Drug: Adenosine (ADO)
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine (ADO) pretreatment (10‐min 100 microgkg(‐1)min(‐1) ADO) before application of the aortic cross‐clamp and antegrade 1 mmol l(‐1) adenosine high‐potassium ([K(+)]=20 mol l(‐1)) cold blood cardioplegia
Study: 19683936
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) received antegrade cold (12 degrees C) high‐potassium ([K(+)]=20 mol l(‐1)) institute blood cardioplegia
Study: 17257464
Drug: Cannabidiol/THC buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol/THC buccal spray
Study: 15023508
Drug: Integrated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated group therapy (IGT)
Study: 11464374
Drug: Bed rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bed rest (Group L)
Study: 9581366
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health awareness campaign (test group)
Study: 31371165
Drug: Symptom-based adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-based adjustment (SBA) with as-needed beclomethasone 80 μg and rescue short-acting β-agonist
Study: 31371165
Drug: Provider-based guideline-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider-based guideline-directed adjustment (PBA) with maintenance beclomethasone 80 μg/d (6-11 years) or 160 μg/d (12-17 years)
Study: 29337780
Drug: Ascorbic acid-enriched
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid-enriched polyethylene glycol solution plus bisacodyl
Study: 28094466
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy alone for CHD with β-blockers
Study: 28094466
Drug: Early revascularization
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early revascularization for CHD with β-blockers
Study: 23307544
Drug: Cognitive-enhancing drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-enhancing drugs
Study: 21590281
Drug: Rimonabant (CB(1)
Normalized name: BroveX CB
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Rimonabant (CB(1) receptor antagonist) co-administered with ketamine
Study: 18499880
Drug: Metoclopramide oral
Normalized name: metoclopramide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide oral solution 2 mg t.i.d.
Study: 18499880
Drug: Metoclopramide tablets
Normalized name: Metoclopramide Tablets
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide tablets 5 mg t.i.d.
Study: 9422301
Drug: Atracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 5%